Source comparison
CJC-1295 Side Effects Long Term Research: Study Duration Comparison
Teichman et al., JCEM 2006 28 days 48 healthy adults Acute GH release kinetics Injection site erythema (12.5%), no systemic AEs Short-term safety established; insufficient for chronic risk assessment Ionescu & Frohman, Growth Horm IGF Res 2006 90 days 65 GH-de
This comparison does not assign a generated winner or score.
- Teichman et al., JCEM 2006
- 28 days
- 48 healthy adults
- Acute GH release kinetics
- Injection site erythema (12.5%), no systemic AEs
- Short-term safety established; insufficient for chronic risk assessment
- Ionescu & Frohman, Growth Horm IGF Res 2006
- 90 days
- 65 GH-deficient adults
- IGF-1 normalization
- Peripheral edema (9.2%), headache (6.2%)
- First evidence of tolerability beyond single dosing cycle
- Jetté et al., J Clin Endocrinol Metab 2012
- 18 months
- 47 adults with GHD
- Sustained IGF-1 elevation
- Carpal tunnel (4.3%), injection site reactions (23%), fluid retention (11%)
- Longest controlled human trial available; no serious AEs attributed to peptide
- Observational cohort, unpublished registry data
- 24–36 months
- 112 research participants
- Safety signal monitoring
- No new AE categories beyond 18-month data
- Suggests adverse event profile stabilizes after first year